# Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

> **NCT02879318** · PHASE2 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 180 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT02879318
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-07
- **Primary completion:** 2020-08-03
- **Final completion:** 2025-03-14
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2025-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02879318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02879318, "Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02879318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*